Your browser doesn't support javascript.
loading
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Delimpasi, Sosana; Mateos, Maria Victoria; Auner, Holger W; Gavriatopoulou, Maria; Dimopoulos, Meletios A; Quach, Hang; Pylypenko, Halyna; Hájek, Roman; Leleu, Xavier; Dolai, Tuphan Kanti; Sinha, Dinesh Kumar; Venner, Christopher P; Benjamin, Reuben; Garg, Mamta Krishnan; Doronin, Vadim; Levy, Yair; Moreau, Philippe; Chai, Yi; Arazy, Melina; Shah, Jatin; Shacham, Sharon; Kauffman, Michael G; Richardson, Paul G; Grosicki, Sebastian.
Afiliación
  • Delimpasi S; General Hospital Evangelismos, Athens, Greece.
  • Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain.
  • Auner HW; The Hugh and Josseline Langmuir Centre for Myeloma Research, Imperial College London, London, UK.
  • Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Quach H; St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.
  • Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
  • Hájek R; Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
  • Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.
  • Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.
  • Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.
  • Venner CP; Cross Cancer Institute, Edmonton, Alberta, Canada.
  • Benjamin R; Kings College Hospital NHS Foundation Trust, London, UK.
  • Garg MK; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Doronin V; City Clinical Hospital #40, Moscow, Russian Federation.
  • Levy Y; Baylor University Medical Center, Dallas, Texas, USA.
  • Moreau P; University of Nantes, Nantes, France.
  • Chai Y; Karyopharm Therapeutics, Newton, Massachusetts, USA.
  • Arazy M; Karyopharm Therapeutics, Newton, Massachusetts, USA.
  • Shah J; Karyopharm Therapeutics, Newton, Massachusetts, USA.
  • Shacham S; Karyopharm Therapeutics, Newton, Massachusetts, USA.
  • Kauffman MG; Karyopharm Therapeutics, Newton, Massachusetts, USA.
  • Richardson PG; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Grosicki S; Medical University of Silesia, Katowice, Poland.
Am J Hematol ; 97(3): E83-E86, 2022 03 01.
Article en En | MEDLINE | ID: mdl-34882831
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Enfermedades Renales / Mieloma Múltiple Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2022 Tipo del documento: Article País de afiliación: Grecia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Enfermedades Renales / Mieloma Múltiple Tipo de estudio: Clinical_trials Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2022 Tipo del documento: Article País de afiliación: Grecia